Stargardt Disease Clinical Trials in Dallas, Texas

9 studies are recruiting for stargardt disease in Dallas, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of ALK-001 on the Progression of Stargardt Disease

   This study evaluates the efficacy and safety of investigational study drug ALK-001 in participants 8 to 45 years of age, inclusive, with symptoms and signs of autosomal recessive Stargardt disease (STGD)

   Stage

   Phase 3

   Ages

   8 to 45

   Site

   Retina Foundation of the Southwest, Dallas, Texas

   Locations

   14 in total

   Run by

   Alkeus Pharmaceuticals, Inc.

   See if you can join NCT07419334 on ClinicalTrials.gov

2. A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions

   Macular dystrophies are a group of inherited eye conditions that affect the macula. The macula is in the center of the retina, the light sensitive part at the back of the eye. In people with macular dystrophies, some of the cells in the macula gradually stop working and may die over time. This lead…

   Stage

   Phase 1

   Ages

   6 and older

   Site

   Retina Foundation of Southwest, Dallas, Texas

   Locations

   3 in total

   Run by

   Astellas Institute for Regenerative Medicine

   See if you can join NCT07734064 on ClinicalTrials.gov

3. A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults

   Macular dystrophies are a group of inherited eye conditions that affect the macula. The macula is in the center of the retina, the light sensitive part at the back of the eye. In people with macular dystrophies, some of the cells in the macula gradually stop working and may die over time. This lead…

   Stage

   Not phased

   Ages

   6 and older

   Site

   Retina Foundation of the Southwest, Dallas, Texas

   Locations

   15 in total

   Run by

   Astellas Pharma Global Development, Inc.

   See if you can join NCT07425574 on ClinicalTrials.gov

4. A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)

   The purpose of the 039-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-039 in participants with Stargardt disease secondary to a biallelic mutation of the ABCA4 gene. The study will also assess initial efficacy following AAVB-039 administration.

   Stage

   Phase 1

   Ages

   8 to 55

   Site

   Retina Foundation of the Southwest, Dallas, Texas

   Locations

   9 in total

   Run by

   AAVantgarde Bio Srl

   See if you can join NCT07161544 on ClinicalTrials.gov

5. Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)

   This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials.

   Stage

   Not phased

   Ages

   5 and older

   Site

   Retina Foundation of Texas, Dallas, Texas

   Locations

   8 in total

   Run by

   Ascidian Therapeutics, Inc

   See if you can join NCT06445322 on ClinicalTrials.gov

6. Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

   This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Retina Foundation of the Southwest, Dallas, Texas

   Locations

   10 in total

   Run by

   Ascidian Therapeutics, Inc

   See if you can join NCT06467344 on ClinicalTrials.gov

7. An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

   This is an Observational Study to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene This is a multicenter study which will enroll approximately 75 subjects

   Stage

   Not phased

   Ages

   12 to 65

   Site

   Retina Foundation of the Southwest, Dallas, Texas

   Locations

   20 in total

   Run by

   Splice Bio

   See if you can join NCT06435000 on ClinicalTrials.gov

8. A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)

   This Phase 1/2 study will evaluate the safety, tolerability, and preliminary efficacy of subretinal SB-007 administration to determine dose selection in subjects with Stargardt's Type 1 (STGD1). This is a multicenter study which will enroll approximately 57 subjects, followed up over a 96 week peri…

   Stage

   Phase 1

   Ages

   12 to 65

   Site

   Retina Foundation of the Southwest, Dallas, Texas

   Locations

   5 in total

   Run by

   Splice Bio

   See if you can join NCT06942572 on ClinicalTrials.gov

9. A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT

   The goal of this observational study is to assess the reliability and validity of the 9-object MLSDT for evaluation of participants with moderate to severe vision impairment when tested without a wearable low-vision magnifying aid (eGlasses) and then with eGlasses. These results will be compared to…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Retina of North Texas,, Dallas, Texas

   Run by

   Nanoscope Therapeutics Inc.

   See if you can join NCT06805474 on ClinicalTrials.gov